InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Thursday, 10/03/2019 12:40:21 PM

Thursday, October 03, 2019 12:40:21 PM

Post# of 9726
News: $SNGX Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer

Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ: SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head and neck cancer, an unmet medical need. And, as the release date approaches...

Read the whole news SNGX - Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNGX News